Active-comparator new-user cohort studies with an appropriate design have consistently demonstrated dementia risk reduction with SGLT2 inhibitor users with diabetes across different regions [12,13,14,15,16,17,18,19,20]
Navigate the healthcare industry Healthcare Brew covers pharmaceutical developments, health startups, the latest tech, and how it impacts hospitals and providers to keep administrators and providers informed
doi:10.1016/j.molbiopara.2009.12.011
The side-chain guanidyl group of Arg454 interacts with the carboxylate moiety of glycine to orient the substrate for attack on the acyl-phosphate intermediate (Herrera et al., Unlike other organisms, some plants synthesize glutathione analogs in which -alanine, serine, or glutamate replaces glycine in the tripeptide (Figure 4A)